Status:
UNKNOWN
Evaluation of the Safety and Efficacy of Azvudine and Paxlovid in the Treatment of Hospitalized Patients With COVID-19
Lead Sponsor:
Xiao Li，MD
Conditions:
Paxlovid
Azvudine
Eligibility:
All Genders
18+ years
Brief Summary
In this retrospective study, we aimed to evaluate the clinical efficacy and safety of two antiviral drugs on COVID-19 and inpatients with existing complications in the First Affiliated Hospital of Sha...
Detailed Description
We conducted a single center retrospective cohort study on hospitalized patients with severe acute respiratory syndrome coronavirus type 2 infection who received treatment with nimatevir/ritonavir tab...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- 1\. The patient's admission time is from December 1,2022 to January 31,2023. 2. The patient has used either Paxlovid or azivudine tablets during admission. 3. Age ≥ 18 years old. Exclusion Criteria：
- 1\. Patients using other antiviral drugs. 2. Patients with incomplete clinical data.
Exclusion
Key Trial Info
Start Date :
June 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT05996770
Start Date
June 1 2024
End Date
December 30 2024
Last Update
April 3 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.